Performance evaluation of human cytokines profiles obtained by various multiplexed-based technologies underlines a need for standardization.
Fiche publication
Date publication
juillet 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIZARD Gérard
Tous les auteurs :
Dupuy AM, Kuster N, Lizard G, Ragot K, Lehmann S, Gallix B, Cristol JP
Lien Pubmed
Résumé
BACKGROUND: Multiplexed methods permit simultaneous quantification of multiple cytokines. As several manufacturers offer reagents to quantify the same cytokines on a single instrument, comparison of the distribution should be made to determine whether these data are comparable from one assay to another. METHODS: We performed the quantification of cytokines in serum samples with three commercially available assays: Cytometric Bead Array (CBA), Protein Biochip Array Technology (PBAT), and Luminex Technology analysis. Using detection limit and reference range of the three commercial multiplex technologies, we evaluated: 1) the overall distribution of cytokines; and 2) the clinical impact. RESULTS: The three cytokines, IL-1beta, IL-1alpha and IL-4, cannot be measured by these methods because of the high number of non-detected data (>50%). By contrast, four cytokines as IL-8, VEGF, MCP-1 and EGF exhibited a low percentage of non-detected data whatever method was used. The comparison of the percentage of samples with values higher than the respective reference range of each method reported an absence of clinical concordance (Cohen's kappa-test
Référence
Clin Chem Lab Med. 2013 Jul;51(7):1385-93